Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.
तुलना करने के लिए मीट्रिक्स | 2552 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध2552पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −7.6x | 7.0x | −0.5x | |
PEG अनुपात | 0.42 | 0.00 | 0.00 | |
क़ीमत/बुक | −14.0x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 7.4x | 3.5x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 68.8% | 27.3% | 49.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.9% | 8.2% | अनलॉक करें |